Optimize Financial Inc Acquires New Shares in Dyne Therapeutics, Inc. $DYN

Optimize Financial Inc acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 14,761 shares of the company’s stock, valued at approximately $154,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Exome Asset Management LLC acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at $2,703,000. Caxton Associates LLP acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at $157,000. Voleon Capital Management LP acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at $624,000. Goldman Sachs Group Inc. lifted its stake in shares of Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after purchasing an additional 366,183 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Sanford C. Bernstein initiated coverage on shares of Dyne Therapeutics in a research note on Tuesday, June 24th. They issued a “market perform” rating and a $13.00 price objective for the company. Oppenheimer cut their target price on shares of Dyne Therapeutics from $34.00 to $13.00 and set an “outperform” rating for the company in a research report on Wednesday, August 6th. Raymond James Financial raised shares of Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $31.00 to $35.00 in a research report on Monday, August 25th. Evercore ISI reissued an “outperform” rating on shares of Dyne Therapeutics in a research report on Friday, July 11th. Finally, Royal Bank Of Canada cut their target price on shares of Dyne Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $34.07.

Insiders Place Their Bets

In related news, CEO John Cox sold 2,640 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the sale, the chief executive officer owned 199,539 shares of the company’s stock, valued at $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Stock Down 0.4%

Shares of DYN opened at $13.25 on Wednesday. The company has a 50-day simple moving average of $10.96 and a 200-day simple moving average of $11.13. The firm has a market capitalization of $1.88 billion, a P/E ratio of -3.43 and a beta of 1.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $37.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.02. On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.